Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKTR-255 and Lisocabtagene Maraleucel in R/R Large B-Cell Lymphoma
NCT05359211Phase 1Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Dec 2022
- Primary completion
- Sep 2025
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NKTR-255 in diffuse large B-cell lymphoma (DLBCL), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Incidence of adverse events at 30 days, Dose-limiting toxicity rates at 21 days and 2 more. Started Dec 2022; status: completed.
02
Drugs
NKTR-255
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05359211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05359211.